Updates are available Correction dated 2024-02-28
Click to view Correction: https://doi.org/10.1038/s41375-024-02184-z
-
Authors
Flygt, Hjalmar https://orcid.org/0000-0002-8912-2324
Söderlund, Stina
Richter, Johan https://orcid.org/0000-0002-0374-6823
Saussele, Susanne https://orcid.org/0000-0003-0357-5785
Koskenvesa, Perttu
Stenke, Leif
Mustjoki, Satu https://orcid.org/0000-0002-0816-8241
Dimitrijevic, Andreja https://orcid.org/0000-0002-0125-1886
Stentoft, Jesper
Majeed, Waleed
Roy, Lydia
Wolf, Dominik
Dreimane, Arta
Gjertsen, Bjørn Tore
Gedde-Dahl, Tobias
Ahlstrand, Erik
Markevärn, Berit
Hjorth-Hansen, Henrik
Janssen, Jeroen
Olsson-Strömberg, Ulla
- License Information
-
More Information
Article History
Received: 1 November 2023
Revised: 25 December 2023
Accepted: 8 January 2024
First Online: 26 January 2024
Change Date: 28 February 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41375-024-02184-z
Competing interests
: Study drug was provided by BMS. DW have received study support and honoraria from BMS, Novartis, Pfizer, Austrian Orphan Pharma and Incyte. SS have received honoraria from BMS, Novartis, Incyte, Roche and research support from Incyte and Novartis. In addition, the Nordic CML Study group have other projects supported by Incyte, Pfizer and Austrian Orphan Pharma.
